Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries-Reference-Cited by-同舟云学术

Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries

Published:2024-04-25 Issue: Volume: Page:1-12
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Bharmal Murtuza¹^ORCID,Katsoulis Ioannis²,Chang Jane³,Graham Alex²,Stavropoulou Apostolina²,Jhingran Priti⁴,Pashos Chris L⁴^ORCID

Affiliation:

1. Global Evidence & Value Development Oncology, EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA

2. Market Access Transformation, Fleet, GU51 2UJ, UK

3. Value & Evidence, Pfizer, New York, NY 10001-2192, USA

4. Genesis Research Group, Hoboken, NJ 07030, USA

Funder

Merck

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-1004

Reference56 articles.

1. US Food and Drug Administration. Framework for FDA's real-world evidence program (2018). www.fda.gov/media/120060/download

2. Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

3. A Comparison of 7 Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies

4. EUnetHTA. An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report. EUnetHTA Joint Action 3 (2016–2020): WP7 research and analysis activity: 1-152; Annex 1 (2017). www.eunethta.eu/wp-content/uploads/2018/02/WP7-Activity-1-Report.pdf

5. Wang T. CIRS RD Briefing 83 – HTA outcomes in Australia Canada and Europe 2016–2020 (2021). www.cirsci.org/publications/cirs-rd-briefing-83-hta-outcomes-in-australia-canada-and-europe-2016-2020/